Matthew J. Matasar, MD, on Indolent NHL: New Data on Copanlisib Plus Rituximab

April 12, 2021 By The ASCO Post Staff

Matthew J. Matasar, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III results of the CHRONOS-3 trial, which showed that copanlisib plus rituximab led to a 48% reduction in the risk of disease progression or death compared with placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (Abstract CT001).

Related Content